Mesoblast Limited Company Profile (NASDAQ:MESO)

About Mesoblast Limited (NASDAQ:MESO)

Mesoblast Limited logoMesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MESO
  • CUSIP: N/A
  • Web: www.mesoblast.com
Capitalization:
  • Market Cap: $462.94 million
  • Outstanding Shares: 92,176,000
Average Prices:
  • 50 Day Moving Avg: $6.46
  • 200 Day Moving Avg: $8.22
  • 52 Week Range: $4.01 - $12.50
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -12.98
  • P/E Growth: -0.29
Sales & Book Value:
  • Annual Revenue: $2.41 million
  • Price / Sales: 208.45
  • Book Value: $6.09 per share
  • Price / Book: 0.89
Profitability:
  • EBIDTA: ($86,990,000.00)
  • Net Margins: -3,184.70%
  • Return on Equity: -14.79%
  • Return on Assets: -11.55%
Debt:
  • Current Ratio: 1.73%
  • Quick Ratio: 1.73%
Misc:
  • Average Volume: 26,122 shs.
  • Beta: 2.78
  • Short Ratio: 25.32
 

Frequently Asked Questions for Mesoblast Limited (NASDAQ:MESO)

What is Mesoblast Limited's stock symbol?

Mesoblast Limited trades on the NASDAQ under the ticker symbol "MESO."

When will Mesoblast Limited make its next earnings announcement?

Mesoblast Limited is scheduled to release their next quarterly earnings announcement on Monday, November, 13th 2017. View Earnings Estimates for Mesoblast Limited.

Where is Mesoblast Limited's stock going? Where will Mesoblast Limited's stock price be in 2017?

6 equities research analysts have issued 12 month price targets for Mesoblast Limited's stock. Their predictions range from $8.50 to $20.00. On average, they anticipate Mesoblast Limited's stock price to reach $14.25 in the next year. View Analyst Ratings for Mesoblast Limited.

What are analysts saying about Mesoblast Limited stock?

Here are some recent quotes from research analysts about Mesoblast Limited stock:

  • 1. Maxim Group analysts commented, "Mesoblast reported year-end (FYE June 30) with a net loss of $77M and ended the period with $46M in cash. The company completed a $40M raise on August 29, 2017 and currently has $84M in cash on the balance sheet." (8/30/2017)
  • 2. Cantor Fitzgerald analysts commented, "Accelerating Chronic Heart Failure (CHF). Mesoblast recently outlined its plans to seek a potential accelerated approval pathway for its MPC-150-IM product in patients with advanced cardiac heart failure. Based on the significant unmet need and serious complications of the disease, the company believes its 159-patient Phase 2b study with end-stage (Class IV) CHF patients that require left ventricular device (LVAD) assistance could support an accelerated approval. Completion of enrollment is imminent, and top-line data from the study are expected in 1Q18. The primary endpoint of the study will assess the number of times patients are able to undergo weaning off LVAD assistance. Enrolling in Advanced CHF. Mesoblast is also conducting a large 600-patient Phase 3 study in advanced (Class II/III) CHF patients that could serve as a confirmatory study and has enrolled over 400 patients so far. This study will assess recurrent, non-fatal, HF-related major adverse cardiac events between MPC-treated and sham-treated patients. Data are expected to be released in 2019. Attractive Markets. We estimate a large, multi-billion-dollar market for Mesoblast’s cell portfolio (combined royalties of ~$6 billion) when it reaches peak market penetration." (8/30/2017)
  • 3. According to Zacks Investment Research, "Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic, 'off-the-shelf' cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions. " (6/24/2017)

Who are some of Mesoblast Limited's key competitors?

Who are Mesoblast Limited's key executives?

Mesoblast Limited's management team includes the folowing people:

  • Silviu Itescu, Chief Executive Officer, Executive Director
  • William A. Burns, Vice Chairman of the Board
  • Paul Hodgkinson, Group Chief Financial Officer
  • Peter Howard, General Counsel, Corporate Executive
  • Charlie Harrison, Company Secretary
  • Brian Jamieson, Independent Non-Executive Chairman of the Board
  • Donal Paul O'Dwyer, Non-Executive Independent Director
  • Eric A. Rose M.D., Non-Executive Independent Director
  • Michael R. Spooner, Non-Executive Independent Director
  • Ben-Zion Weiner Ph.D., Non-Executive Independent Director

When did Mesoblast Limited IPO?

(MESO) raised $69 million in an initial public offering (IPO) on Friday, November 13th 2015. The company issued 5,700,000 shares at $12.10 per share. J.P. Morgan and Credit Suisse acted as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

Who owns Mesoblast Limited stock?

Mesoblast Limited's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Prudential PLC (1.78%), Capital Research Global Investors (0.52%), Goldman Sachs Group Inc. (0.28%), Princeton Capital Management Inc. (0.20%) and Osborn Williams & Donohoe LLC (0.03%). View Institutional Ownership Trends for Mesoblast Limited.

Who sold Mesoblast Limited stock? Who is selling Mesoblast Limited stock?

Mesoblast Limited's stock was sold by a variety of institutional investors in the last quarter, including Prudential PLC and Princeton Capital Management Inc.. View Insider Buying and Selling for Mesoblast Limited.

Who bought Mesoblast Limited stock? Who is buying Mesoblast Limited stock?

Mesoblast Limited's stock was acquired by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc.. View Insider Buying and Selling for Mesoblast Limited.

How do I buy Mesoblast Limited stock?

Shares of Mesoblast Limited can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mesoblast Limited's stock price today?

One share of Mesoblast Limited stock can currently be purchased for approximately $5.45.


MarketBeat Community Rating for Mesoblast Limited (NASDAQ MESO)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  109 (Vote Outperform)
Underperform Votes:  71 (Vote Underperform)
Total Votes:  180
MarketBeat's community ratings are surveys of what our community members think about Mesoblast Limited and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Mesoblast Limited (NASDAQ:MESO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $14.25 (161.47% upside)

Analysts' Ratings History for Mesoblast Limited (NASDAQ:MESO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/31/2017CIBCInitiated CoverageOutperform -> Outperform$16.00HighView Rating Details
8/31/2017Oppenheimer Holdings, Inc.Initiated CoverageOutperform$16.00HighView Rating Details
8/30/2017Maxim GroupSet Price TargetBuy$14.00HighView Rating Details
8/30/2017Cantor FitzgeraldReiterated RatingBuy$20.00HighView Rating Details
7/18/2017Credit Suisse GroupSet Price TargetHold$11.00LowView Rating Details
4/3/2017ScotiabankReiterated RatingHold$8.50LowView Rating Details
3/7/2016J P Morgan Chase & CoDowngradeOverweight -> Neutral$9.00 -> $10.00N/AView Rating Details
2/25/2016Chardan CapitalReiterated RatingHoldN/AView Rating Details
11/24/2015Ladenburg Thalmann Financial ServicesReiterated RatingBuyN/AView Rating Details
(Data available from 9/20/2015 forward)

Earnings

Earnings History for Mesoblast Limited (NASDAQ:MESO)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Mesoblast Limited (NASDAQ:MESO)
Current Year EPS Consensus Estimate: $-0.77 EPS
Next Year EPS Consensus Estimate: $-0.42 EPS

Dividends

Dividend History for Mesoblast Limited (NASDAQ:MESO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Mesoblast Limited (NASDAQ:MESO)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Mesoblast Limited (NASDAQ:MESO)
Latest Headlines for Mesoblast Limited (NASDAQ:MESO)
Source:
DateHeadline
americanbankingnews.com logoMesoblast Limited (MESO) Cut to Sell at ValuEngine
www.americanbankingnews.com - September 15 at 9:50 PM
americanbankingnews.com logoMesoblast Limited (MESO) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - September 7 at 4:46 AM
finance.yahoo.com logoETFs with exposure to Mesoblast Ltd. : September 6, 2017
finance.yahoo.com - September 5 at 10:09 PM
americanbankingnews.com logoHead-To-Head Contrast: Mesoblast Limited (MESO) versus Organovo Holdings (ONVO)
www.americanbankingnews.com - September 4 at 4:06 PM
finance.yahoo.com logoMesoblast Ltd. :MESO-US: Earnings Analysis: 2017 By the Numbers : September 1, 2017
finance.yahoo.com - September 2 at 6:14 AM
finance.yahoo.com logoMesoblast Ltd. :MESO-US: Earnings Analysis: 2017 By the Numbers : September 1, 2017
finance.yahoo.com - September 2 at 6:14 AM
americanbankingnews.com logoMesoblast Limited to Post FY2018 Earnings of ($1.16) Per Share, Cantor Fitzgerald Forecasts (MESO)
www.americanbankingnews.com - September 1 at 11:52 AM
americanbankingnews.com logoCIBC Initiates Coverage on Mesoblast limited (MESO)
www.americanbankingnews.com - August 31 at 2:32 PM
americanbankingnews.com logoMesoblast limited (MESO) Research Coverage Started at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - August 31 at 9:50 AM
streetinsider.com logoUPDATE: Oppenheimer Starts Mesoblast Limited (MESO) at Outperform - StreetInsider.com
www.streetinsider.com - August 31 at 7:11 AM
americanbankingnews.com logoMesoblast Limited (MESO) Given a $14.00 Price Target at Maxim Group
www.americanbankingnews.com - August 30 at 11:16 AM
streetinsider.com logoMesoblast (MESO) Says it Completed Institutional Entitlement Offer for Fully Underwritten A$50.7M Capital Raise - StreetInsider.com
www.streetinsider.com - August 30 at 6:29 AM
globenewswire.com logoMesoblast Operational Highlights and Financial Results for the Fourth Quarter and for the Year Ended 30 June 2017 - GlobeNewswire (press release)
globenewswire.com - August 30 at 6:29 AM
fool.com logoMesoblast Limited looks a long way from take off - Motley Fool Australia
www.fool.com.au - August 30 at 6:29 AM
finance.yahoo.com logoMesoblast Operational Highlights and Financial Results for the Fourth Quarter and for the Year Ended 30 June 2017
finance.yahoo.com - August 30 at 6:29 AM
fool.com logoWhy the Mesoblast limited share price plunged 10% this morning - Motley Fool Australia
www.fool.com.au - August 29 at 1:30 AM
seekingalpha.com logoMesoblast launches A$50.7M equity offering to existing shareholders
seekingalpha.com - August 27 at 12:59 AM
globenewswire.com logoMesoblast Outlines Potential Pathway to Accelerated Market Entry for MPC-150-IM in Advanced Chronic Heart Failure - GlobeNewswire (press release)
globenewswire.com - August 25 at 8:24 AM
globenewswire.com logoMesoblast Outlines Potential Pathway to Accelerated Market Entry for MPC-150-IM in Advanced Chronic Heart Failure - GlobeNewswire (press release)
globenewswire.com - August 25 at 8:24 AM
americanbankingnews.com logoCantor Fitzgerald Reiterates Buy Rating for Mesoblast Limited (MESO)
www.americanbankingnews.com - August 23 at 9:30 AM
streetinsider.com logoForm 6-K MESOBLAST LTD For: Aug 18 - StreetInsider.com
www.streetinsider.com - August 19 at 12:36 AM
streetinsider.com logoMesoblast Limited (MESO) Reports Positive Trial Results of ... - StreetInsider.com
www.streetinsider.com - August 17 at 2:37 AM
americanbankingnews.com logoMesoblast Limited (MESO) PT Set at $14.00 by Maxim Group
www.americanbankingnews.com - August 16 at 8:26 PM
americanbankingnews.com logoMesoblast Limited (MESO) Rating Reiterated by Cantor Fitzgerald
www.americanbankingnews.com - August 16 at 4:30 PM
finance.yahoo.com logoPositive Trial Results of Mesoblast Cell Therapy in Post-Traumatic Osteoarthritis Published In Arthritis Research & Therapy
finance.yahoo.com - August 16 at 6:06 AM
americanbankingnews.com logoMesoblast Limited (MESO) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - August 13 at 4:38 AM
americanbankingnews.com logoMesoblast Limited (MESO) Downgraded by BidaskClub to Strong Sell
www.americanbankingnews.com - July 29 at 2:52 PM
americanbankingnews.com logoIcon Plc (ICLR) vs. Mesoblast Limited (MESO) Head-To-Head Survey
www.americanbankingnews.com - July 21 at 2:26 PM
americanbankingnews.com logoCredit Suisse Group Analysts Give Mesoblast Limited (NASDAQ:MESO) a $11.00 Price Target
www.americanbankingnews.com - July 20 at 12:58 AM
americanbankingnews.com logoMesoblast Limited (NASDAQ:MESO) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - July 19 at 10:10 PM
reuters.com logoBRIEF-Mesoblast Ltd files ‍ for $180 million American depositary shares representing ordinary shares
www.reuters.com - July 11 at 1:37 AM
americanbankingnews.com logoMesoblast Limited (MESO) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - June 24 at 7:10 AM
globenewswire.com logoMesoblast Rheumatoid Arthritis Trial Results Presented at EULAR ... - GlobeNewswire (press release)
globenewswire.com - June 22 at 8:43 AM
americanbankingnews.com logoMesoblast Limited (MESO) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - June 13 at 8:10 AM
streetinsider.com logoCantor Fitzgerald Starts Mesoblast Limited (MESO) at Overweight; 'Underappreciated Late-Stage Cell Therapies' - StreetInsider.com
www.streetinsider.com - June 9 at 11:43 PM
prnewswire.com logoCreative Medical Technology Holdings Develops Platform Aimed at Augmenting All Mesenchymal Stem Cell Therapies for Lower Back Pain
www.prnewswire.com - June 7 at 6:09 PM
americanbankingnews.com logoMesoblast limited (MESO) Receives New Coverage from Analysts at Cantor Fitzgerald
www.americanbankingnews.com - June 7 at 6:02 PM
finance.yahoo.com logoETFs with exposure to Mesoblast Ltd. : June 5, 2017
finance.yahoo.com - June 5 at 7:10 PM
finance.yahoo.com logoMesoblast Ltd. :MESO-US: Earnings Analysis: Q3, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 7:52 PM
americanbankingnews.com logoMesoblast limited (MESO) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - May 27 at 10:04 PM
reuters.com logoBRIEF-Mesoblast says qtrly loss attributable $9.8 mln
www.reuters.com - May 26 at 3:59 AM
seekingalpha.com logoMesoblast Ltd. 2017 Q3 - Results - Earnings Call Slides
seekingalpha.com - May 26 at 3:58 AM
reuters.com logoUPDATE 1-Australia's Mesoblast posts narrower quarterly loss, rise in R&D costs
www.reuters.com - May 25 at 4:33 AM
globenewswire.com logoMesoblast Operational Highlights and Financial Results for the Period Ended March 31, 2017 - GlobeNewswire (press release)
globenewswire.com - May 24 at 11:33 PM
fool.com logoIs the Mesoblast limited share price good value? - Motley Fool Australia
www.fool.com.au - May 24 at 11:33 PM
finance.yahoo.com logoMesoblast Operational Highlights and Financial Results for the Period Ended March 31, 2017
finance.yahoo.com - May 24 at 6:33 PM
americanbankingnews.com logoMesoblast limited (MESO) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 19 at 12:08 AM
finance.yahoo.com logoETFs with exposure to Mesoblast Ltd. : May 9, 2017
finance.yahoo.com - May 9 at 6:12 PM
americanbankingnews.com logoMesoblast limited (MESO) Given Daily Media Impact Rating of 0.44
www.americanbankingnews.com - May 3 at 12:20 AM
americanbankingnews.com logoMesoblast limited (MESO) Getting Positive Press Coverage, Report Finds
www.americanbankingnews.com - April 29 at 7:42 PM

Social

Chart

Mesoblast Limited (MESO) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by MarketBeat.com Staff